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Interleukin-6 (IL-6) induced STAT3 activation is viewed as crucial for multiple tumor growth and
metastasis, including colon cancer. However, the molecular mechanisms remain largely unexplored.
Here, we show that expression of ubiquitin-speciﬁc protease 7 (USP7), a deubiquitylating enzyme, is
decreased in STAT3-positive tumors. IL-6 administration or transfection of a constitutively activated
STAT3 in SW480 cells also repressed USP mRNA expression. Using luciferase reporter and ChIP assay,
we found that STAT3 bound to the promoter region of USP7 and inhibited its activity through
recruiting HDAC1. As a result of the decline of USP7 expression, endogenous P53 protein level was
decreased. Thus, our results suggest a previously unknown STAT3-USP7-P53 molecular network
controlling colon cancer development.
Structured summary of protein interactions::
STAT3 physically interacts with HDAC1 by anti bait coimmunoprecipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction whereby it stabilizes P53 protein [6,7]. It is shown that theAberrant IL-6 and its down-stream STAT3 signaling in cancer
cells have emerged as a major mechanism for cancer initiation and
development [1,2]. However, in normal physiology, IL-6 induced
STAT3 activation is tightly controlled, due to the existence of nega-
tive feedback mechanisms. Besides, STAT3 signaling is crucial for
inﬂammatory cell-mediated transformation and tumor progression
[3]. Recent evidence shows a crucial role for STAT3 in selectively
inducing and maintaining a procarcinogenic inﬂammatory micro-
environment, both at the initiation of malignant transformation
and during cancer development [3]. In addition, it is suggested that
STAT3 is highly interconnected with NF-jB signaling, which has
been recognized as amajor pathway responsible for both inﬂamma-
tion-induced carcinogenesis and anti-tumor immunity [4]. Hence,
STAT3 is a promising target to redirect inﬂammation for cancer
therapy. It will be beneﬁt to understand its roles in cancer.
The ubiquitin-speciﬁc protease, UPS7, also known as the herpes
simplex virus associated ubiquitin-speciﬁc protease (HAUSP), is an
evolutionarily conserved protein which was originally isolated as a
binding partner of the herpes simplex virus protein Vmw110/ICP0
[5]. USP7 has key roles in the P53 tumor suppressor pathway,chemical Societies. Published by E
Li), zhangxuelifxh@hotmail.N-terminal domain of USP7 binds two closely spaced 4-residue
sites in P53, falling between P53 residues 359–367 [6]. Overexpres-
sion of catalytically inactive USP7 in cells promotes P53 binding to
its target sequences and P21 expression, without increasing the
levels of P53 protein. Thus, USP7 positively regulates P53 through
multiple molecular mechanisms.
Here, we show that mRNA and protein levels of USP7 are mark-
edly decreased in colon cancers. We also suggest that IL-6 induced
STAT3 activation represses USP7 expression, leading to the degra-
dation of P53. Our ﬁndings thus link STAT3 signaling directly with
the P53 pathway, which have profound biological and therapeutic
implications for cancer and other inﬂammatory diseases.
2. Materials and methods
2.1. Tissue samples
Primary colon tumor tissues, distant normal colon tissues were
collected from either routine therapeutic surgery or gastrointesti-
nal endoscopy at our department. All samples were obtained with
informed consent and approved by central hospital of Fengxian
district clinic institutional review board.
2.2. Cell culture
HEK293T, SW480, SW620, SW1116, HCT 116 and HT-20 cell
lines were cultured in Dulbecco modiﬁed Eagle’s mediumlsevier B.V. All rights reserved.
Fig. 1. Down-regulation of USP7 in colon cancer tissues. (A and B) mRNA and
protein levels of USP7 were analyzed by real-time PCR and Western Blot in 25 colon
cancer tissues or adjacent normal tissues. (C) Phosphorylation of STAT3 was
analyzed in 4 colon cancer tissues or normal tissues. (D) The relationship between
USP7 and phosphorylated STAT3 were analyzed in HEK293T cells and several colon
cancer cell lines, including SW480, SW620, HCT 116 and HT-20.
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100 mg/ml streptomycin.
2.3. Reagents
IL-6 was purchased from Merck, China. The following antibod-
ies were purchased: anti-STAT3 (Cell Signaling), anti-p-STAT3
(Santa Cruz), anti-USP7 (Abcam), anti-P53 (Santa Cruz), anti-
HDAC1 (Santa Cruz) anti-b-Actin (sigma) and anti-Ubiquitin
(Santa Cruz).
2.4. siRNA
Cells were plated onto six well plates grown to 50% conﬂuence
and then transfected with 25 nM siGENOME non-targeting siRNA,
human STAT3 or HDAC1 siGENOME SMART pool (Thermo Fisher
Scientiﬁc) using DharmaFECT1 transfection reagent according to
the manufacturer’s protocol. After 24 h incubation under nor-
moxia, the transfection medium was replaced with complete med-
ium and the cells were incubated under hypoxia for the indicated
time. Total RNA and cell lysates were collected for Real-time PCR
and Western blot analysis, respectively.
2.5. RNA extraction, cDNA synthesis and real-time analysis
Total RNAs were isolated from tissues or cells by TRIzol reagent,
and reverse transcriptions were performed by Takara RNA PCR kit
(Takara, China) following the manufacturer’s instructions. In order
to quantify the transcripts of the interest genes, real-time PCR was
performed using a SYBR Green Premix Ex Taq (Takara, Japan) on
Light Cycler 480 (Roche, Switzerland). The primer sequences used
are available upon request.
2.6. Immunoprecipitation
Cells were lysed in 6 ml of lysis buffer (50 mM Tris–HCl pH 7.5,
150 mM NaCl, 0.5% Nonidet P40, Roche complete EDTA-free prote-
ase inhibitor cocktail) for 20 min with gentle rocking at 4 C. Ly-
sates were cleared using centrifugation (13000 rpm, 10 min), the
supernatant was subjected to immunoprecipitation (IP) with
10 lg of anti-STAT3 antibody or mouse IgG overnight at 4 C with
gentle inversion. Protein A/G beads were added for additional 4 h
at4 C. Beads containing immune complexes were washed with
1 ml ice cold lysis buffer four times followed by three 1 ml Tris Buf-
fered Saline (TBS) washes. Precipitates were denatured in Laemmli
(gel loading) buffer at 95 C for 5 min.
2.7. Transient transfections and luciferase assays
Human USP7 promoter was cloned into PGL3 plasmid (Prome-
ga). All the transient transfections were performed by Lipofecta-
min 2000 (Invitrogen), according to the manufacturer’s
instructions. For luciferase reporter assay, HEK293T cells were
seeded in 24-well plates and transfected with the indicated plas-
mids. Cells were harvested 36 h after transfection. Luciferase
activity was measured using the Dual Luciferase Reporter Assay
System (Promega, USA).
2.8. ChIP assays
A chromatin immunoprecipitation (ChIP) assay kit was used
(Upstate, USA). In brief, SW480 cells were ﬁxed with formalde-
hyde. DNA was sheared to fragments at 200–1000 bp using soni-
cations. The chromatin were incubated and precipitated with
antibodies against the indicated antibodies or IgG (Santa Cruz,
USA).2.9. Statistical analysis
Values were shown as mean ± SEM. Statistical differences were
determined by a Student’s t test. Statistical signiﬁcance is dis-
played as ⁄(P < 0.05), ⁄⁄(P < 0.01) or ⁄⁄⁄(P < 0.001).
3. Results
3.1. Down-regulation of USP7 is a frequent event in colon cancer
tissues
First, we analyzed USP7 expression in 25 paired colon cancer
and adjacent non-tumor colon tissues by way of real-time PCR
and western blot. We found that USP7 was signiﬁcantly down-reg-
ulated in cancer tissues (Fig. 1A). We then employed Western blot
with anti-USP7 antibody to test USP7 protein expression in those
clinic samples including 4 colon cancer samples and their adjacent
normal tissues. The results showed that USP7 was low expressed in
colon cancer samples (Fig. 1B). Moreover, we also observed the
expression of phosphorylated STAT3 in those colon cancer samples
(Fig. 1C), which indicates the persistent activation of STAT3 in
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tween USP7 and phosphorylated STAT3, several colon cancer cell
lines were analyzed by western blot. As shown in Fig. 1D, we also
observed the highly activated STAT3 and lower expression of USP7,
suggesting that STAT3 might be an upstream regulator of USP7
expression.
3.2. Negatively regulation of USP7 by IL-6 and STAT3 activation
As suggested by the down-regulation of USP7 and persistent
activation of STAT3 in colon cancers, we then used real-time PCR
and western blot to conﬁrm the correlation between STAT3 activity
and USP7 expression in SW480 cell lines. As shown in Fig. 2A and B,
IL-6 treatment reduced USP7 levels in SW480 cells in a dose depen-
dent manner. Besides, overexpression of a constitutively activated
STAT3 (STAT3C) also repressed the expression levels of USP7
(Fig. 2C and D). Conversely, siRNA knockdown of STAT3 in
SW480 cells increased USP7 mRNA and protein levels (Fig. 2E
and F). The similar results were also observed in HCT 116 cells
(Supplementary Fig. 1), further conﬁrming that USP7 expression
was negatively regulated by STAT3.
3.3. STAT3 represses USP7 expression through recruitment of HDAC1
We next determined whether STAT3 could be a transcriptional
regulator of the USP7 gene. We transfected SW480 tumor cells
with a reporter vector encoding Luciferase under control of the
USP7 promoter (PGL3-USP7.WT). Concurrent expression of STAT3C
with the USP7 reporter construct decreased USP7 promoter activ-
ity (Fig. 3A), which was abrogated by mutation of the STAT3
DNA-binding site in the USP7 promoter (Fig. 3A). The inhibitoryFig. 2. Effect of STAT3 on the USP7 expression. (A and B) mRNA and protein levels of USP
without IL-6 (0, 5 or 20 ng/ml). (C, D) mRNA and protein levels of USP7 were analyzed by r
STAT3C. (E and F) SW480 cells were transfected for non-speciﬁc control or STAT3 siRNAeffect of STAT3 on USP7 promoter activity was also shown in
HEK293T cells (data not shown). We next carried out chromatin
immunoprecipitation (ChIP) assays to assess whether STAT3 di-
rectly binds the USP7 promoter. STAT3 protein bound the USP7
promoter was signiﬁcantly increased in SW480 cells treated with
IL-6 (Fig. 3B).
Negative regulation of gene transcription by STAT3 has been
partly attributed to the recruitment of histone deacetylase (HDAC)
activities [8]. Consistent with this, HDAC class I and class II inhib-
itor trichostatin A (TSA) abolished STAT3-mediated repression of
USP7 transcription (Fig. 3C) [9], suggesting that STAT3 recruits nu-
clear HDAC to confer its transcriptional repression roles. Indeed,
simultaneous transfections of STAT3 and HDAC1, but not HDAC2
or HDAC3 further inhibited the luciferase reporter (Fig. 3D). In-
deed, endogenous STAT3 could interact with HDAC1 in SW480
cells (Fig. 3E). In addition, siRNA knockdown of HDAC1 could sig-
niﬁcantly upregulated USP7 expression (Fig. 3F and G). ChIP assays
also suggested the recruitment of HDAC1 to the promoter region of
USP7 in SW480 cells upon IL-6 treatment (Fig. 3H). Moreover,
occupancy of HDAC1 was impaired in cells with STAT3 knockdown,
indicating that the interaction of STAT3 was essential of the
recruitment of HDAC1 on the promoter regions of USP7 (Fig. 3I).
Thus these studies suggested that STAT3 repressed USP7 transcrip-
tion via interactions with HDAC1.
3.4. STAT3 activation decreases the P53 stability
Since the protective role of USP7 in the P53 pathway, we deter-
mined whether STAT3 activation could affect the P53 stability. As
shown in Fig. 4A and B, P53 protein levels were markedly
decreased in SW480 cells treated with IL-6 or transfected with7 were analyzed by real-time PCR and Western Blot in SW480 cells treated with or
eal-time PCR andWestern Blot in SW480 cells transfected with empty vector (EV) or
. Endogenous mRNA and protein levels of STAT3 and USP7 were determined.
Fig. 3. HDAC1 was involved in the regulation of USP7 by STAT3. (A) SW480 cells were co-transfected with the indicated plasmids for 36 h, and the luciferase activity was
measured. (B) Two antibodies (anti-IgG and -STAT3) were used in the ChIP assays using SW480 cells treated with or without IL-6. (C) SW480 cells co-transfected with the
indicated plasmids were treated with TSA, and the luciferase activity was measured. (D) SW480 cells were co-transfected with the indicated plasmids for 36 h, and the
luciferase activity was measured. (E) Lysates of SW480 cells were subjected to immunoprecipitation (IP) with Mouse IgG or STAT3 antibody followed by western blot with
indicated antibodies. (F and G) SW480 cells were transfected for non-speciﬁc control or HDAC1 siRNA. Endogenous mRNA and protein levels of STAT3 and USP7 were
determined. (H) Two antibodies (anti-IgG and -HDAC1) were used in the ChIP assays in SW480 cells treated with or without IL-6. (I) Occupancy of HDAC1 on the promoter
regions of USP7 was determined in SW480 cells transfected with control or STAT3 siRNA, in the absence or presence of IL-6.
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protein levels (Fig. 4C). Moreover, ubiquitination of P53 was also
increased in SW480 cells treated with IL-6 (Fig. 4D) or transfected
with STAT3C (data not shown). Moreover, we found that protein
levels of P53 were decreased in colon cancer tissues from patients,
which suggested the inverse-correlation between phosphorylated
STAT3 and P53 (Fig. 4E). Together, our data indicate that STAT3
activation could decrease P53 stability.
4. Discussion
Recent evidence shows a crucial role for STAT3 in selectively
inducing and maintaining a procarcinogenic inﬂammatorymicroenvironment, both at the initiation of malignant trans-
formation and during cancer development [10]. In addition, it is
suggested that STAT3 is highly interconnected with NF-jB
signaling, which has been recognized as a major pathway responsi-
ble for both inﬂammation-induced carcinogenesis and anti-tumor
immunity [11,12]. Hence, STAT3 is a promising target to redirect
inﬂammation for cancer therapy.
The tumor suppressor protein p53 was reported to be an impor-
tant target of USP7. Besides, USP7 was shown to be involved in
DNA damage response [13]. Here, we show that mRNA and protein
levels of USP7 are markedly decreased in human colon cancer cells
treated with Interlukin-6 (IL-6). We also suggest that STAT3 activa-
tion down-regulates USP7 expression, leading to the degradation
Fig. 4. Effect of STAT3 activation on the P53 stability. (A) HeLa cells were transfected with the indicated plasmids, the protein level of P53 were analyzed by Western Blot. (B)
SW480 cells were treated with or without IL-6, the protein level of P53 were analyzed by Western Blot. (C) SW480 cells were transfected with the indicated siRNAs, the
protein level of P53 was analyzed by Western Blot. (D) Lysates of SW480 cells treated with or without IL-6, were subjected to IP with P53 antibody followed by western blot
with indicated antibodies. (E) Protein levels of P53 in 4 colon cancer tissues (C) or normal tissues (N) were determined by Western Blot.
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USP7-p53 pathway, which have profound biological and therapeu-
tic implications for cervical carcinoma.
In summary, our results provide new insight into how STAT3
activation could inﬂuence the P53 pathway, which could provide
a potential mechanism by which STAT3 inﬂuences cell-cycle pro-
gression. Ultimately, these data may provide the rationale for the
development of speciﬁc STAT3 inhibitors as efﬁcient anti-cancer
drugs.
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Supplementary data associated with this article can be found, in
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